Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to -$6.3 million.

  • Aytu Biopharma's Cash from Financing Activities fell 12692.03% to -$6.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.3 million, marking a year-over-year increase of 540876.49%. This contributed to the annual value of $15.4 million for FY2025, which is 132369.26% up from last year.
  • Aytu Biopharma's Cash from Financing Activities amounted to -$6.3 million in Q4 2025, which was down 12692.03% from $2.3 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Cash from Financing Activities high stood at $13.6 million for Q3 2022, and its period low was -$6.4 million during Q1 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $720500.0 (2024), whereas its average is $1.3 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 209047.62% in 2024, then soared by 111657.3% in 2025.
  • Aytu Biopharma's Cash from Financing Activities (Quarter) stood at $6.6 million in 2021, then tumbled by 128.3% to -$1.9 million in 2022, then soared by 93.24% to -$126000.0 in 2023, then crashed by 2090.48% to -$2.8 million in 2024, then tumbled by 126.92% to -$6.3 million in 2025.
  • Its last three reported values are -$6.3 million in Q4 2025, $2.3 million for Q3 2025, and $13.0 million during Q2 2025.